IP Library › Granted Patent US 12,630,823
Granted Patent B2
US 12,630,823 · App. 18/179,325 · Granted May 19, 2026

Neurodegenerative disorders

Inventors: Pavlos Alifragis (Egham, GB); Linda Popplewell (Egham, GB); John George Dickson (Egham, GB); Amninder Sangha (Egham, GB)
Assignee: Teesside University
C12N15/113C07K14/4711C12N2310/11C12N2310/314C12N2310/315C12N2310/3233C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,630,823
App. No.
18/179,325
Granted
May 19, 2026
Kind
B2
Abstract

The invention relates to neurodegenerative disorders, and in particular to novel oligonucleotides for treating such conditions, for example Alzheimer's disease. The invention provides novel antisense oligonucleotides, and compositions comprising such oligos, and therapies and methods for treating neurodegenerative disorders. The invention includes genome editing techniques for achieving similar results as using the novel antisense oligonucleotides.

Claims (23)

1 . An antisense oligonucleotide (AON) capable of reducing or preventing exon 7 and/or exon 8 inclusion into an amyloid precursor protein (APP) mRNA produced by splicing from an APP transcript wherein the AON comprises internucleosidic linkages which are chemically modified or wherein the AON comprises a phosphorodiamidate morpholino oligomer (PMO) and wherein the AON comprises a nucleotide sequence selected from the group consisting of SEQ ID Nos: 6, 7, 8, 9, 10, 12, 13, 14 and 15.

2 . A pharmaceutical composition comprising a therapeutically effective amount of one or more AON according to claim 1 .

3 . A method of treating or ameliorating a neurodegenerative disorder in a subject, the method comprising: administering to a subject in need of such treatment, a therapeutically effective amount of one or more AON according to claim 1 .

4 . An antisense oligonucleotide (AON) capable of reducing or preventing exon 7 and/or exon 8 inclusion into an amyloid precursor protein (APP) mRNA produced by splicing from an APP transcript wherein the AON comprises internucleosidic linkages which are chemically modified or wherein the AON comprises a phosphorodiamidate morpholino oligomer (PMO) wherein a protein made by skipping exon 7 and 8 comprises the following features:

1) Exon 6 is joined with exon 9, maintaining the reading frame and resulting in a protein with 695 amino acids;

2) the Kunitz-type protease inhibitor domain (KPI), which is within exon 7, is removed; and/or

3) a domain sharing homology with the OX-2 antigen of thymus-derived lymphoid cells, which is within exon 8, is removed.

5 . An AON according to claim 1 , wherein the AON is capable of binding to and/or is complementary to a target region within:

(i) the 3′ part of intron 6-7 and/or the 5′ part of exon 7 of the APP gene;

(ii) exon 7 of the APP gene;

(iii) the 3′ part of exon 7 and/or the 5′ part of intron 7-8 of the APP gene;

(iv) the 3′ part of intron 7-8 and/or the 5′ part of exon 8 of the APP gene;

(v) exon 8 of the APP gene; and/or

(vi) the 3′ part of exon 8 and/or the 5′ part of intron 8-9 of the APP gene.

6 . An AON according to claim 5 , wherein the AON is complementary to at least 8 nucleotides in the target region, or from 8 to 50 nucleotides, or from 12 to 50 nucleotides, in the target region, or wherein the AON has a length of from 18 to 42 nucleotides, or from 22 to 42, or from 27 to 39 nucleotides.

7 . An AON according to claim 1 , wherein when the AON is capable of reducing or preventing exon 7 inclusion into an APP mRNA produced by splicing from an APP transcript, the target region for the AON is between 150 nucleotides upstream of the intron 6/exon 7 junction (−150) and 150 nucleotides downstream of the exon 7/intron 7 junction (+150).

8 . An AON according to claim 1 , wherein the AON target region spans 15 nucleotides upstream and 150 nucleotides downstream of exon 7 of the human APP gene (−15 to +50), and is represented as SEQ ID NO: 5.

9 . An AON according to claim 1 , wherein when the AON is capable of reducing or preventing exon 8 inclusion into an APP mRNA produced by splicing from an APP transcript, the target region for the AON is between 150 nucleotides upstream of the intron 7/exon 8 junction (−150) and 150 nucleotides downstream of the exon 8/intron 8 junction (+150).

10 . An AON according to claim 1 , wherein the AON is complementary to a target region within, or adjacent to, exon 8, and comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 12, 13, 14 and 15.

11 . A method according to claim 3 wherein the neurodegenerative disease is Alzheimer's disease.

12 . A method according to claim 11 , wherein one or more AON for causing exon 7 skipping is used in combination with one or more AON for causing exon 8 skipping, and wherein any one of the AON selected from the group consisting of SEQ ID NO: 6, 7, 8, 9 and 10 is used in combination with any one of the AON selected from the group consisting of SEQ ID NO: 12, 13, 14 or 15.

13 . A method according to claim 3 , wherein one or more AON for causing exon 7 skipping is used in combination with one or more AON for causing exon 8 skipping, and wherein any one of the AON is selected from the group consisting of SEQ ID NO: 6, 7, 8, 9 and 10 is used in combination with any one of the AON selected from the group consisting of SEQ ID NO: 12 13, 14 or 15.

14 . The pharmaceutical composition of claim 2 comprising a pharmaceutically acceptable vehicle.

Priority Claims (1)
GB 1803010 · Feb 26, 2018 · national
Continuity (2)
Continuation 16975700
Related Publication 20250011772A1 · Jan 9, 2025
References Cited (72)
US 5187153A · Cordell · 1993 [cited by applicant]
US 10655165B2 · Carlson · 2020 [cited by examiner]
US 20030023997A1 · Peraus · 2003 [cited by applicant]
US 20120122113A1 · Prions · 2012 [cited by applicant]
EP 1191097A1 · 2002 [cited by applicant]
WO 2004023973A3 · 2004 [cited by applicant]
WO 2010120262A1 · 2010 [cited by applicant]
WO 2012018257A1 · 2012 [cited by applicant]
WO 2012178122A3 · 2012 [cited by applicant]
WO 2017064308A1 · 2017 [cited by applicant]
Siva et al. (“Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.” Nucleic acid therapeutics 24.1 (2014): 69-86). [cited by examiner]
Nguyen, Khue Vu. (β-Amyloid precursor protein (APP) and the human disease AIMS neuroscience 6.4 (2019): 273.). [cited by examiner]
Pascal Smith et al., “In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs”, J. Neurochemistry, vol. 116, No. 2, Jan. 1, 2011, pp. 240-247, New York, NY. [cited by applicant]
Eugene V. Makeyev et. al., “The MicoRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing”, Molecular Cell, vol. 27, No. 3, Aug. 3, 2007, pp. 435-448, Amsterdam, NL. [cited by applicant]
Xiaomin Yin et al., “Tetrahydroxystilbene glucoside modulates amyloid precursor protein processing via activation of AKT-GSK3β pathway in cells and in APP/PS1 transgenic mice”, Biocehm. Biophys. Research Communcations, … [cited by applicant]
R. Donev et. al., “A role for SC35 and hnRNPA1 in the determination of amyloid precursor protein isoforms”, Molecular Psychiatry, vol. 12, No. 7, Mar. 13, 2007, pp. 681-690, GB. [cited by applicant]
Shafiul Alam et al., “Alternative splicing regulation of APP exon 7 by RBFox proteins”, Neurochemistry International, vol. 78, Dec. 1, 2014, pp. 7-17, Amsterdam, NL. [cited by applicant]
Apostolia Fragkouli et al., “Neuronal ELAVL proteins utilize AUF-1 as a co-partner to induce neuron-specific alternative splicing of APP”, Scientific Reports, vol. 7, No. 1, Mar. 14, 2017, Springer Nature. [cited by applicant]
Todd E. Golde et al., “Expression of β amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR” , Neuron, vol. 4, No. 2, Feb. 1, 1990, pp. 253… [cited by applicant]
Ling Li et al., “Polymorphic tetranucleotide repeat site within intron 7 of the β-amyloid precursor protein gene and its lack of association with Alzheimer's disease”, Hum Genet, vol. 103, 1998, pp. 86-89, Springer-Verl… [cited by applicant]
Takeshi Yamada et al., “Neuron-specific splicing of the Alzheimer amyloid precursor protein gene in a mini-gene system”, Biochem. Biophys. Res. Comm., vol. 195, No. 1, Aug. 31, 1993, pp. 442-448, Academic Press. [cited by applicant]
Ioannis Zalachoras et al., “Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain”, Frontiers Mol. Neurosci., vol. 4, article 10, Jul. 19, 2011. [cited by applicant]
Annemieke Aartsma-Rus et al., “Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms”, Mol. Ther., vol. 17, No. 3, Sep. 23, 2008, pp. 548-553, Elsevier. [cited by applicant]
Annemieke Aartsma-Rus et al., “Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications”, RNA, vol. 13, (2007), pp. 1609-1624, Cold Spring Harbor Laboratory Press. [cited by applicant]
Alvarez-Erviti, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted episomes, Nature Biotechnology 29(4),:341-45, Apr. 2011 (published online Mar. 20, 2011). [cited by applicant]
Belyaev, et al., The Transcriptionally Active Amyloid Precursor Protein (APP) Intracellular Domain is Preferentially Produced from the 695 Isoform of APP in a β-Secretase-dependent Pathway, The Journal of Biological Che… [cited by applicant]
Bordji, et al., Activation of Extrasynaptic, But Not Synaptic, NMDA Receptors Modifies Amyloid Precursor Protein Expression Pattern and Increases Amyloid-β Production, The Journal of Neuroscience, 30(47):15927-15942, No… [cited by applicant]
Chiorini, et al., Cloning and Characterization of Adeno-Associated Virus Type 5, Journal of Virology, 73(2):1309-1319, Feb. 1999. [cited by applicant]
Dayton, et al., The advent of AAV9 expands applications for brain and spinal cord gene delivery, Expert Opin. Biol. Ther., 12(6): 757-766, 2012. [cited by applicant]
Desmet, et al., Human Splicing Finder: an online bioinformatics tool to predict splicing signals, Nucleic Acids Research. 37(9): 14 pages, doi:10.1093/nar/gkp215, published online Apr. 2009. [cited by applicant]
Ding, et al., Sfold web server for statistical folding and rational design of nucleic acids, Nucleic Acids Research, 32, Web Server issue: W135-W141, DOI: 10.1093/nar/gkh449, 2004. [cited by applicant]
Ding, et al., Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH dependent drug release, PNAS, 107(42):18143-18148, Oct. 19, 2010. [cited by applicant]
Egholm et al., PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules, Nature, 365:566-568, Oct. 7, 1993. [cited by applicant]
Flammang, et al., Evidence that the Amyloid-β Protein Precursor Intracellular Domain, AICD, Derives from β-Secretase-Generated C-Terminal Fragment, Journal of Alzheimer's Disease, 30:145-153, 2012, DOI10.3233/JAD-2012-1… [cited by applicant]
Goldgaber, et al., Characterization and Chromosomal Localization of a cDNA Encoding Brain Amyloid of Alzheimer's Disease, Science, 235:877-880, Feb. 20, 1987, doi10.1242/jcs.048090. [cited by applicant]
Goodger, et al., Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway, J. Cell Science, 122(20):3703-3714, 2009, doi:10.1242/jcs.048090. [cited by applicant]
Gorman, et al., Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc. Natl. Acad. Sci., USA, 95:4929-4934, Apr. 1998. [cited by applicant]
Govindaraju, et al., Backbone-extended pyrrolidine peptide nucleic acids (bepPNA): design, synthesis and DNA/RNA binding studies, The Royal Society of Chemistry, Chem. Comm., 495-497, 2005, published online Dec. 2, 2004… [cited by applicant]
Ho, et al., The Alternatively Spliced Kunitz Protease Inhibitor Domain Alters Amyloid β Protein Precursor Processing and Amyloid β Protein Production in Cultured Cells, J. Biol. Chem., 271(48):30929-30934, 1996. [cited by applicant]
Huang, et al., Alzheimer Mechanisms and Therapeutic Strategies, Cell, 148: 1204-1222, Mar. 16, 2012. [cited by applicant]
Hyman, et al., Kunitz Protease Inhibitor-Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's Disease, J. Neuropathology and Experimental Neurology, 51(1):76-83, Jan. 1992. [cited by applicant]
Kang, et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, 325:733-736, Feb. 19, 1987. [cited by applicant]
König, et al., Retinoic acid induced differentiated neuroblastoma cells show increased expression of the βA4 amyloid gene of Alzheimer's disease and an altered splicing pattern, FEBS, 29(2):305-310, Sep. 1990. [cited by applicant]
Matsui, et al., Expression of APP pathway mRNAs and proteins in Alzheimer's Disease, Brain Research 1161:116-123, 2007, doi:10.1016/jbrainres.2007.05.050. [cited by applicant]
McCarty, et al., Mannitol-facilitated CNS entry of rAAV2 vector signifiantly delayed the neurological disease progression in MPS IIIB mice, Gene Therapy, 16:1340-1352, Jul. 9, 2009. [cited by applicant]
Moir, et al., Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral Aβ Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain, J. Biol. Chem., 273(9): 5013-5019, Feb. 27, 1998. [cited by applicant]
Morita et al., 2′-O,4′-C-Ethylene-bridged nucleic acids (ENA) with nuclease-resistance and high affinity for RNA, Nucleic Acids Research, Supplement No. 1, 241-242, 2001. [cited by applicant]
Müller, et al., Not just amyloid, physiological functions of the amyloid precursor protein family, Nature Reviews | Neuroscience, doi:10.1038/nm.2017.29, published online Mar. 31, 2017. [cited by applicant]
Nielsen et al., Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide, Science 254:1497-1500, Dec. 6, 1991. [cited by applicant]
Palmert et al., The β-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid, Proc. Natl. Acad. Sci., USA, 86:6338-6342, Aug. 1989. [cited by applicant]
Panegyres et al., The effects of excitotoxicity on the expression of the amyloid precursor protein gene in the brain and its modulation by neuroprotective agents, J. Neural Transm 105:463-478 (1998). [cited by applicant]
Popplewell, et al., Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene, Molecular Therapy 17(3):554-561, Mar. 2009. [cited by applicant]
Rosi et al., Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation, Science 312:1027-1029, 2006, DOI:10.1126/science.112559. [cited by applicant]
Sandbrink et al., APP gene family: unique age-associated changes in splicing of Alzheimer's βA4-amyloid protein precursor, Neurobiology of Disease, 1:13-24, 1994. [cited by applicant]
Sandbrink, et al., APP Gene Family Alternative Splicing Generates Functionally Related Isoforms, Ann NY Acad Sci 777:281-287, Jan. 17, 1996. [cited by applicant]
Sandbrink, et al., Expression of the APP Gene Family in Brain Cells, Brain Development and Aging, Gerontology, 43:119-131, 1997. [cited by applicant]
Schindelin, et al., Fiji: an open-source platform for biological-image analysis, Nature Methods, 9(7):676-682, Jul. 2012, DOI:10.1038/NMETH.2019. [cited by applicant]
Shariati, et al., Redundancy and divergence in the amyloid precursor protein family, FEBS Letters 587:2036-2045, May 23, 2013. [cited by applicant]
Smith, et al., In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs, J. Neurochem., 116:240-247, 2011. [cited by applicant]
Spillantini, et al., Expression and cellular localization of amyloid β -protein precursor transcripts in normal human brain and in Alzheimer's disease, Molecular Brain Research 6:143-150, 1989. [cited by applicant]
Suter, et al., Double-target antisense U7 snRNAs promote efficint skipping of an aberrant exon in three human β—thalassemic mutations, Human Molecular Genetics, 8(13):2415-2423, 1999. [cited by applicant]
Tanaka, et al., Three types of amyloid protein precursor mRNA in human brain: their differential expression in Alzheimer's disease, Biochemical and Biophysical Research Communications 157(2):472-479, Dec. 15, 1988. [cited by applicant]
Tanzi, et al., Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus, Science 235:880-884, 1987. [cited by applicant]
Thompson, et al., Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting position-specific gap penalties and weight matrix choice, Nucleic Acids Research, 22(22):4673-… [cited by applicant]
Thompson, et al., The CLUSTAL_X windows interface: flexible strategies for multple sequence alignment aided by quality analysis tools, Nucleic Acids Research 25(24):4876-4882, 1997. [cited by applicant]
Vuong, et al., The neurogenetics of alternative splicing, Nature Reviews | Neroscience, 17:265-281, May 2016. [cited by applicant]
Weidemann, et al., Identification, Biogenesis, and Localization of Precursors of Alzheimer's Disease A4 Amyloid Protein, Cell, 57:115-126, Apr. 7, 1989. [cited by applicant]
Willoughby et al., β-Amyloid Precursor Protein (APP) and APP-RNA Are Rapidly Affected by Glutamate in Cultured Neurons, Journal Molecular Neuroscience, 6:257-276 1995. [cited by applicant]
Yoshikai, et al., Genomic organization of the human amyloid beta-protein precursor gene, Gene 87:257-263, 1990. [cited by applicant]
Zhan, et al., APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer's disease and non-demented aged subjects: a mu… [cited by applicant]
Zuker, M., Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Research, 31(13):3406-3415, 2003, DOI:10.1093/nar/gkg595. [cited by applicant]
Mills et al., Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases, Neurobiology of Aging 33: 1012.e11-1012.e24, 2012, doi:10.1016/j.neurobiolagaing.2011.10.030. [cited by applicant]